Arbutus Biopharma (ABUS) Tops Q2 EPS by 1c

Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.65 million versus the consensus estimate of $6.18 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer